All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Charles Mullighan, St. Jude Children's Research Hospital, Memphis, US. We asked, How are advances in ALL genomics informing new treatment approaches?
How are advances in ALL genomics informing new treatment approaches?
Mullighan begins by highlighting the impact advances in genomics have had on ALL diagnosis and treatment, such as RNA sequencing. He goes into more detail about subtypes and the shortcomings of a gene panel approach for ALL. Mullighan discusses the benefits for patients, such as improved risk stratification, and optimization of novel and conventional therapies. Finally, he highlights the value in tracking clonal mutations and outlines the role of genomics in T-ALL.
AALL1331: blinatumomab improves outcomes for some low-risk pediatric and AYA patients with first relapse of B-ALL
Survival remains poor for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescent, and young adult (AYA)...
Recurrent immature Ig gene rearrangements in TP53-mutated B-precursor adult ALL
During the premature stage of lymphopoiesis, immunoglobulin (Ig) and T-cell receptor (TCR) genes undergo rearrangements — key mechanisms of the physiological process....
Subscribe to get the best content related to ALL delivered to your inbox